Gadicke Ansbert's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Aug 31, 2026
- Accession no.
- 0001231919-26-001135
- Filed
- Aug 31, 2026, 6:25 PM ET
- Trade date
- Aug 27-31, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $615.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 10% Owner |
| Evnin LukeCIK 0001134657 | 10% Owner |
| Foley ToddCIK 0001473930 | 10% Owner |
| MPM BioVentures 2014, L.P.CIK 0001609492 | 10% Owner |
| MPM BioVentures 2014 (B), L.P.CIK 0001609493 | 10% Owner |
| MPM Asset Management Investors BV2014 LLCCIK 0001609495 | 10% Owner |
| MPM Bioventures 2018 (B), L.P.CIK 0001729504 | 10% Owner |
| MPM Asset Management Investors BV2018 LLCCIK 0001734817 | 10% Owner |
| MPM BioVentures 2014 LLCCIK 0001765021 | 10% Owner |
| MPM BioVentures 2014 GP LLCCIK 0001765091 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Common Stock | SSaleDisposed | −38,922 | $7.20 | −$280,238.4 | 4,279,426 | Indirect | |
| Aug 28, 2026 | Common Stock | SSaleDisposed | −3,733 | $7.01 | −$26,168.33 | 4,275,693 | Indirect | |
| Aug 31, 2026 | Common Stock | SSaleDisposed | −44,259 | $6.99 | −$309,370.41 | 4,231,434 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.